MedTrace Logo

Irritation and Sensitization Study of d-Amphetamine Transdermal System

NCT04094025 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 229

Last updated 2020-08-24

No results posted yet for this study

Summary

The study will assess skin irritation as well as sensitization for d-ATS patch in healthy subjects.

Conditions

  • Cumulative Irritation and Sensitization

Interventions

DRUG

dATS

d-Amphetamine Transdermal System

Sponsors & Collaborators

  • Noven Therapeutics

    lead INDUSTRY

Principal Investigators

  • George Harb, MD · Noven Pharmaceuticals, Inc.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-12-02
Primary Completion
2020-05-16
Completion
2020-05-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04094025 on ClinicalTrials.gov